+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

KDA WAITE-GRIFFIN SBMA FELLOWSHIP

Kennedy's Disease Association

Terry Waite and Patrick Griffin met at a 1999 conference for Families of Spinal Muscular Atrophy. During a special breakout session for patients with SBMA, the men discovered that they both had created websites to share information about Kennedy’s Disease and both had plans to start a non-profit organization to support research into SBMA. Terry and Patrick combined their email lists and, with a lot of help from Terry’s wife Susanne, established the Kennedy’s Disease Association (KDA) in 2000. Today, KDA has grown to over 1,500 associates from many countries. To honor these men, KDA is pleased to offer a career-development fellowship for SBMA research.

An important KDA goal is to support young researchers and encourage them to include research in SBMA in their future career plans. The Waite-Griffin Fellowship provides $75,000 to cover salary/benefits for the applicant for one year, plus an additional $2,000 for travel or education. The awardee is expected to devote at least 70% of their time to SBMA research. Any extra funds may be used for supplies.

The KDA Waite-Griffin Fellowship award is for a period of one year. The fellowship may be extended for an additional year assuming demonstrated progress in SBMA research and the availability of funds.

Important Dates and Deadlines: Your proposals must be received by Monday June 1, 2026. The KDA will send a confirmation email within three days of receipt.

AI Based Application Success Predictor

🧬 1. Strong Focus on Kennedy’s Disease / SBMA (Non-Negotiable)

Projects must directly address:
- Spinal and Bulbar Muscular Atrophy (SBMA)
Includes:
- Disease mechanisms
- Biomarkers
- Therapeutics
- Patient care and quality of life

👉 General neuromuscular disease research without SBMA relevance → low success probability

🎯 2. Clear Translational & Therapeutic Relevance (Top Predictor)

The Kennedy's Disease Association strongly prioritizes:
- Research leading toward:
  - Treatments
  - Symptom management
  - Clinical trials

👉 Key question:
“Will this move the field closer to effective SBMA treatment or improved patient care?”

🔄 3. Strong Mechanistic Understanding of SBMA Biology (Critical)

High-success areas include:

Androgen receptor toxicity
Polyglutamine expansion biology
Neuromuscular degeneration pathways
Muscle-neuron interaction
Protein aggregation mechanisms

👉 Mechanistically grounded translational studies are highly favored.

💊 4. Therapeutic Development & Drug Repurposing (Major Differentiator)

Competitive projects often involve:

Targeted therapeutics
Gene therapy
RNA-based approaches
Neuroprotective interventions
Drug repurposing strategies

👉 Therapy-oriented proposals score especially highly.

🧪 5. Feasible, Pilot-Scale Rare Disease Research

Because SBMA is a rare disease:
- Funding often supports:
  - Pilot studies
  - Proof-of-concept research
  - Preliminary therapeutic testing

👉 Realistic aims and achievable milestones are essential.

👩‍🔬 6. Rare Disease Expertise & Neuromuscular Research Experience

Strong applicants usually demonstrate:

Expertise in:
- Neuromuscular disease
- Motor neuron disorders
- Rare neurodegenerative disease

👉 Prior SBMA/ALS/muscular atrophy research experience improves competitiveness.

📊 7. Biomarker & Clinical Endpoint Development

Increasing priority areas include:

Biomarker discovery
Disease progression tracking
Functional outcome measures
Imaging or molecular monitoring tools

👉 Clinical trial–enabling research is highly valuable.

🤝 8. Collaboration with SBMA Patient & Research Networks

Competitive projects often involve:

Neuromuscular clinics
Rare disease consortia
Patient registries
Multicenter collaborations

👉 Access to SBMA patients and samples strengthens feasibility.

🌍 9. Patient-Centered Outcomes & Quality of Life

Strong interest in:
- Symptom management
- Mobility/function
- Swallowing/speech issues
- Daily living improvement

👉 Quality-of-life impact is important in rare disease funding.

🚀 10. Innovation in Rare Neuromuscular Therapeutics

High-success innovation areas include:

Precision medicine
Gene silencing
CRISPR/gene editing
AI-assisted biomarker analysis
Personalized neuromuscular therapy

👉 Innovative but feasible approaches perform best.

📈 11. Potential for Future NIH/Foundation Funding

KDA funding often acts as:
- Seed funding for:
  - NIH rare disease grants
  - clinical trials
  - multicenter collaborations

👉 Clear future scalability improves competitiveness.

🌐 12. Dissemination & Community Engagement

Strong proposals often include:

Patient communication plans
Rare disease awareness
Data sharing
Conference/publication strategy

👉 Community connection matters more in rare disease ecosystems.

📊 Summary: Key Predictors (Ranked)

🔥 Highest impact factors:

SBMA/Kennedy’s Disease-specific focus
Translational therapeutic relevance
Mechanistic understanding of disease biology

⚖️ Major differentiators:

Therapeutic development potential
Biomarker/clinical endpoint relevance
Rare disease expertise

📌 Supporting factors:

Feasibility in rare disease context
Collaboration and patient network access
Quality-of-life impact
Future funding scalability

💡 Insider Insight

Compared to NIH or broader neuromuscular funders:

Kennedy's Disease Association is:
👉 highly focused on:
- SBMA-specific translational science
- rare disease therapeutic progress
- patient-centered impact
- practical clinical advancement

👉 Winning formula:
SBMA-focused mechanistic project + therapeutic relevance + feasible rare disease design + strong patient impact

✔️ What wins:

SBMA therapeutic development
Biomarker and clinical endpoint studies
Mechanistic androgen receptor research
Rare disease translational neuromuscular projects

❌ What struggles:

Non-SBMA neurology research
Pure descriptive/basic science
Weak therapeutic relevance
Overly ambitious rare disease studies without feasibility

Specialties

Genetics & Genomics

Others

Eligibility Requirements

Applications are welcome from researchers who are interested in a career in SBMA research and/or patient care. Applicants should be no more than five years from the award of a PhD degree, or no more than five years from the completion of residency/fellowship training for MD or MD/ PhD degrees and be engaged in postdoctoral training. Applicants cannot hold the position of Assistant Professor or higher nor can they have their own laboratory. All applicants must have an established mentor who has a PhD, MD or MD/PhD degree and possesses a well-documented history of accomplishments in the field of SBMA research. All mentors must have primary appointments at academic, public or private, non-profit research institutions.
Applications from the for-profit sector will not be accepted

Sponsor Details

Sponsor Institute/Organizations: Kennedy's Disease Association

Sponsor Type: Corporate/Non-Profit

Address: P.O. Box 1105, Coarsegold, California 93614

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity